"Oncolytic Virus Market"The Oncolytic Virus (OV) therapy landscape is evolving rapidly as this novel immuno-oncology strategy gains traction for its ability to selectively infect, replicate within ...

The official results of the BRACELET-01 (PrECOG 0113) trial have been published in Clinical Cancer Research, detailing the safety and efficacy of pelareorep, an investigational oncolytic virus ...

Researchers have developed the downstream section of a new streamlined production method for an emerging virus class.

Adding the oncolytic virus immunotherapy pelareorep to paclitaxel chemotherapy warrants further investigation in patients with HR+ HER2- metastatic breast cancer whose disease has progressed after ...

The funding will support further preclinical development of UP Oncolytics lead therapy — an oncolytic virus targeting gliomas, the most common form of brain cancer.

Oncolytic virus therapy is not a new discovery, but it may now be positioned as the next major breakthrough in cancer treatment following the success of checkpoint inhibitors in immunotherapy. An ...

Rosalind Franklin University Helix 51 Company UP Oncolytics Secures Wisconsin Economic Development Matching Grant to Advance Oncolytic Virus Therapy for Brain Cancer ...

Our results support the use of VSV as a replication-competent oncolytic virus and demonstrate a new strategy for the treatment of interferon non-responsive tumors.